SRT1720 HCl

目录号:S1129

仅限科研使用

SRT1720 HCl是一种选择性的SIRT1激活剂,无细胞试验中EC50为0.16 μM,对SIRT2和SIRT3的作用弱230倍以上。SRT1720 还可诱导自噬。

SRT1720 HCl Chemical Structure

CAS: 1001645-58-4

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1960.55 现货
RMB 1400.82 现货
RMB 7964.73 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SRT1720 HCl发表文献157篇:

产品安全说明书

Sirtuin抑制剂选择性比较

相关Sirtuin产品

生物活性

产品描述 SRT1720 HCl是一种选择性的SIRT1激活剂,无细胞试验中EC50为0.16 μM,对SIRT2和SIRT3的作用弱230倍以上。SRT1720 还可诱导自噬。
靶点
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
体外研究

SRT1720抗最近的乙酰化酶同系物SIRT2 (EC1.5为37 μM)和SIRT3 (EC1.5 > 300 μM)的最大激活率达781%。SRT1720在氨基末端催化区的变构位点结合到SIRT1酶-肽底物复合物上,降低乙酰化底物的米氏常数值。用SRT1720处理一周后,饲喂的葡萄糖水平降低,处理三周后,饲喂的葡萄糖水平进一步降低,持续处理10周。Rosiglitazone激活PPARγ,已经用于治疗II型糖尿病;而与Rosiglitazone相比,在进行腹膜葡糖糖耐量试验时,用SRT1720处理导致葡萄糖明显降低。SRT1720对用无糖食物喂养的鼠没有作用效果,显示出药理学SIRT1的激活不会产生低血糖。与Rosiglitazone相似,用SRT1720处理4周,明显降低高胰岛素血症,使升高的胰岛素水平恢部分复正常SRT1720处理腓肠肌,通过测定柠檬酸合酶活性发现线粒体各项能力上升15%。[1]高浓度 SRT1720 (15 μM)诱导正常细胞活力轻微下降,约10-20%。SRT1720明显抑制VEGF依赖的 MM 细胞迁移。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  NEnmTo9HfW6ldHnvckBCe3OjeR?= MXS0xsDPxE1? NID0cmg{OMLibXnu MoW0SG1UVw>? NFLWOVhqdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3NEGwOEc,OjZ{NUSxNFQ9N2F-
MC3T3-E1 MUXGeY5kfGmxbjDBd5NigQ>? NGTEdnAyOCEEtV5CpC=> Mn32NUBp M1fTXZJm\HWlZYOgeIhmKFSJRj5Otk1{fGmvdXzheIVlKF[HR1[gdoVt\WG|ZTDpckBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{wrC= M2W4fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2PVc5Lz5{NkGzOlk4QDxxYU6=
MC3T3-E1 M2TvcWZ2dmO2aX;uJGF{e2G7 Ml;ONVAhyrWPwrC= MmTmNVIhcA>? NWS5W2F5emWmdXPld{B1cGViVlXHSkBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IIP0bY12dGG2ZXSgZpkhXEeILd8y MmrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[5O|goRjJ4MUO2PVc5RC:jPh?=
MC3T3-E1 M3vsbmZ2dmO2aX;uJGF{e2G7 M1;sd|IxKM7:TR?= MlXtNUBp Mlzyd5VxeHKnc4Pld{B1cGViVFfGMe6zNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB2ND;wOFIhVUGSIHvpcoF{\SCxcjDTRXBMN0qQSx?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|Nkm3PEc,OjZzM{[5O|g9N2F-
WE-68 MX\BdI9xfG:|aYOgRZN{[Xl? MYqwMVI1KM7:TR?= MoHHNlQhcA>? MlG5bY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> NIjTdYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
SK-ES-1 MWPBdI9xfG:|aYOgRZN{[Xl? NXHKVFVUOC1zMDFOwG0> M3X5dVI1KGh? NU\nT45icW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-N-MC  Mo\nRZBweHSxc3nzJGF{e2G7 NILFVHIxNTJwNTFOwG0> M3r1ZVI1KGh? M2TpeYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCmb4PlJIRmeGWwZHXueIx6 M{nzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
WE-68 NEe5PHZHfW6ldHnvckBCe3OjeR?= MVWyNEDPxE1? NEfXU2MxNTJ2IHi= M1nSNYFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? NFe4b5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
SK-ES-1 MYDGeY5kfGmxbjDBd5NigQ>? NHTDelMyOCEQvF2= NIrlSGkxNTJ2IHi= NETo[Hpi[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? NX\lWHZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
SK-N-MC  MoTaSpVv[3Srb36gRZN{[Xl? MX6zJO69VQ>? MUGwMVI1KGh? MnnCZYN1cX[jdHXzJINie3Cjc3WgN{84 MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
NRK-49F NWLm[o1LTnWwY4Tpc44hSXO|YYm= MUGw5qCUOsLizszN NIL4WIo{PiCq NFPZOJhqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjFOtU1UVUFiYX7kJIZq[nKxbnXjeIlvKGSxc3Wg[IVx\W6mZX70cJk> M4jiOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKyNFA{Lz5{NkCyNlAxOzxxYU6=
NRK-49F Mk\JSpVv[3Srb36gRZN{[Xl? NITRN5Ux6oDVMtMg{txO M4XjSFM3KGh? NGX1O5VmdmijbnPld{BxcG:|cHjvdplt[XSrb36gc4YhTUeIUjDhcoQhWESJRmNOtuKh MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{MkCwN{c,OjZyMkKwNFM9N2F-
NRK-49F MkCySpVv[3Srb36gRZN{[Xl? MnK4NQKBmzMEoN88US=> NUO4cZhkOzZiaB?= M1q1ZoVvcGGwY3XzJHNVSVR|IIDoc5NxcG:{eXzheIlwdg>? M1jPU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKyNFA{Lz5{NkCyNlAxOzxxYU6=
RAW264.7 Mmi4SpVv[3Srb36gRZN{[Xl? M{TTfVEh|ryP NGDud4M3KGh? Mn;2eZBz\We3bHH0[ZMhfGinIILl[JVk\WRiU1nSWFEheHKxdHXpckBweiCvUl7BJIxmfmWuczDifUBpcWeqIHfseYNwe2V? NFXXbXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5N|k6PSd-MkW3PVM6QTV:L3G+
MCF10A NUi0UFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\IWVAuOjBizszN NF:1V5MzPCCq MmnodoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MCF-7 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiwMVIxKM7:TR?= MXOyOEBp NYHhWHZxemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWTBNXBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
T47D NWTYNIE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWwMVIxKM7:TR?= NEP1[JczPCCq NGnzfotz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
SKBR3 NYCzVYw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7rU3YxNTJyIN88US=> MWmyOEBp MkTkdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MmTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
MDA-MB-231 NGTUSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nLelAuOjBizszN M4nWcVI1KGh? NVWwTXBxemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NHT6Z4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
SUM149 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqwMVIxKM7:TR?= M3nt[lI1KGh? NYLzfpVuemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
HS578T NF[yVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnxNE0zOCEQvF2= Mn;0NlQhcA>? MYTy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NU[xS5ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
BT20 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTmWmdHOC1{MDFOwG0> MWKyOEBp NHrSXHlz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MoD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
A459 NH\4bWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPybXkxNTJyIN88US=> NET3OnAzPCCq NXzJSJRoemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M1rpdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
HCT116 M4TFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWyNE0zOCEQvF2= M4[4dFI1KGh? MnrudoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
Neu MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrDcFUxNTJyIN88US=> M{HP[|I1KGh? M1f6PJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Mnq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
MDA-MB-231 NHTnOXdHfW6ldHnvckBCe3OjeR?= Mn\COUDPxE1? M1vkdVghcA>? NIL5e2RqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDhZ4llcWNidnXzbYN2dGG{IH;y[4Fv\WyuZYO= MkTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
MDA-MB-231 MXHGeY5kfGmxbjDBd5NigQ>? MV61JO69VQ>? NX:0[IRWOTZiaB?= MmK0bY5lfWOnczDsfZNwe2:vYXygcYVu[nKjbnWgdIVzdWWjYnnsbZpifGmxbh?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MC3T3-E1 M4Xr[WZ2dmO2aX;uJGF{e2G7 NHjIXogyOCEQvF2= NVju[YNoPjBibXnuxsA> NXjkXlBKe3WycILld5NmeyC2aHWgSmdHNTJvc4TpcZVt[XSnZDDvd5Rmd3C{b4Tl[4VzcW5icnXs[YF{\Q>? MnfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUCwPVUoRjJ3MkmwNFk2RC:jPh?=
MC3T3-E1 NYLxSWFGTnWwY4Tpc44hSXO|YYm= NX3iSpBXOTBizszN NEXFc|c3OCCvaX9CpC=> NHviTYJifHSnboXheIV{KHSqZTDGS2YuOi2rbnT1Z4VlKG:|dHXvdJJwfGWpZYLpckBuWk6DIHX4dJJme3Orb36= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7MEC5OUc,OjV{OUCwPVU9N2F-
MC3T3-E1 Mle5SpVv[3Srb36gRZN{[Xl? MmfZNVAh|ryP MVi2NEBucW8EoB?= MmrLZZR1\W63YYTld{B1cGViRlfGMVIucW6mdXPl[EBwe3Snb4Dyc5Rm\2W{aX6gcXJPSSCneIDy[ZN{cW:w NWe2TG0{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVAxQTVpPkK1NlkxODl3PD;hQi=>
MC3T3-E1 M{XRdmZ2dmO2aX;uJGF{e2G7 MUGxNEDPxE1? MorBOlAhdWmwwrC= M{PVepN2eHC{ZYPz[ZMhfGinIFLNVE01NXO2aX31cIF1\WRiVlXHSkBz\WynYYPl M4S5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEO1OFQ1Lz5{NESzOVQ1PDxxYU6=
MC3T3-E1 NEXxXZNHfW6ldHnvckBCe3OjeR?= MmnJNVAh|ryP NWXmUFZPPjBibXnuxsA> MXHzeZBxemW|c3XzJJRp\SCSR1[y{tEue3SrbYXsZZRm\CCRUFegdoVt\WG|ZR?= NXftWVFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN|M{OzZpPkK0N|M{OzN4PD;hQi=>
MC3T3-E1 MlXxSpVv[3Srb36gRZN{[Xl? MmftNVAh|ryP NFzsU403OCCvaX9CpC=> MVLy[YR2[2W|IITo[UBRT0Z{zsGtd5RqdXWuYYTl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNm Mn3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
MC3T3-E1 M4DqZ2Z2dmO2aX;uJGF{e2G7 MV6xNEDPxE1? MV62NEBucW8EoB?= NFfJVWtifHSnboXheIV{KHSqZTDQS2Yz|rFvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBOTUtzL{KgZY5lKFKjZj2x NHXhT2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|M{Pid-MkSzN|M{OzZ:L3G+
RPE MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M17X[lUhyrWP NE\hOlgyKGh? NVLUPFh5[XS2ZX71ZZRmeyCRQd8yMYlv\HWlZXSg[IVkemWjc3Wgc4Yh[2WubDD2bYFjcWyrdIm= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB|NkmzPEc,OjRyM{[5N|g9N2F-
9607 NYjnSnpsS2WubDDWbYFjcWyrdImgRZN{[Xl? M13SSVEh|ryP Mo\zN|YhcA>? M334Solv[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[2:vcHHy[YQhf2m2aDDt[YxifG:waX6gZYxwdmV? NITEclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlk1QSd-MkO3NlY6PDl:L3G+
9607 MXPGeY5kfGmxbjDBd5NigQ>? MlfaNUDPxE1? NGPFUIw{PiCq M{OyVolv[3KnYYPld{BUUVKWMTDhcoQh\GWlcnXhd4VlKGGlZYT5cIF1\WRvcEWzJIV5eHKnc4Ppc44> M2jUZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K2PVQ6Lz5{M{eyOlk1QTxxYU6=
RPMI.8226 M4nlPWNmdGxiVnnhZoltcXS7IFHzd4F6 MUm3M|ExKM7:TR?= NX;rTml3OjRiaB?= MUHk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NVXmUXF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
U266 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFzvb4c4NzFyIN88US=> MXSyOEBp M4qxeoRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
MM.1S NXjxNGVtS2WubDDWbYFjcWyrdImgRZN{[Xl? M2fQWFcwOTBizszN M4LqelI1KGh? MnTV[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NYTsclM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
KMS12 MnHCR4VtdCCYaXHibYxqfHliQYPzZZk> NWjNZ40{Py9zMDFOwG0> MYmyOEBp NEDDWmZl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NF\1bGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
LR5 MmTYR4VtdCCYaXHibYxqfHliQYPzZZk> NGXiNJQ4NzFyIN88US=> NWXvWYZUOjRiaB?= MmjK[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MmjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
MM.1R MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGOzfYs4NzFyIN88US=> M2nnVlI1KGh? MX3k[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MnL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
Ina6 MoHLR4VtdCCYaXHibYxqfHliQYPzZZk> M2LGVVcwOTBizszN MojaNlQhcA>? NEfzTmxl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
RPMI-8226 MnfsRZBweHSxc3nzJGF{e2G7 NUTVdXlHPy9zMDFOwG0> MoTiNlQhcA>? M3jXXYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjD0bIUhSW6wZYjpckBXMy:SSfMIluKh[XCxcITvd4l{ M3v0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
MM.1R  NX73TJc1SXCxcITvd4l{KEG|c3H5 NYHZPFJyPy9zMDFOwG0> MWiyOEBp MYfpcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5idHjlJGFvdmW6aX6gWkswWEokiKNCpIFxd3C2b4Ppdy=> M{DZOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
H411EC3 M3fGZWZ2dmO2aX;uJGF{e2G7 NIrEOYE2OC9zMECgcm0> NEDVc3k3KGh? MlzybY5kemWjc3XzJHNKWlRzIHHjeIl3cXS7IHnuJJRp\SCycnXz[Y5k\SCxZjDUV2EtKFCHUFPLJIFkfGm4aYT5MEBuWk6DIHzleoVteyCxZjDQZ4syKGGwZDDQ[4My|rFuIHHu[EBmdGW4YYTpcoch\2y3Y3;z[UBxem:mdXP0bY9v MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzMkC5Okc,OjF{MUKwPVY9N2F-
hepatocytes NGL4b25HfW6ldHnvckBCe3OjeR?= M3fEeFExKG6P MnvhOkBp MVvpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzMkC5Okc,OjF{MUKwPVY9N2F-
hepatocytes NHr5NVVHfW6ldHnvckBCe3OjeR?= NYDUUm5rOTBibl2= MX62JIg> NXPIPIFOcW6lcnXhd4V{KEivZ3PyxsBidmUEoFHjZ:Kh\2WwZTDlfJBz\XO|aX;u Ml3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MUKwPVYoRjJzMkGyNFk3RC:jPh?=
U2OS MVXGeY5kfGmxbjDhd5NigQ>? NITKcHMxNjFyIIXN NV:we5JPSWO2aY\heIlwdiCxZjDTTXJVOSCrbjDoeY1idiCXMl;TJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHB3MzDk[YFk\XS7bHH0bY9vKGyndnXsJIF1KDBwMUCgeW0> NXKxOY06RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwOFY1ODlpPkG4NFQ3PDB7PD;hQi=>
A673 NEnieYVyUFSVIHHzd4F6 MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY MUPxTHRUKGG|c3H5 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? M1LTTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 NEO3dW1yUFSVIHHzd4F6 NGe1[FByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NVjoVVZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MmHpdWhVWyCjc4PhfS=> NGfDXppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NFvYcI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MXTxTHRUKGG|c3H5 MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NELMcWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MkfkdWhVWyCjc4PhfS=> NHPFVJNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NEK5Z|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NXH2Sm06eUiWUzDhd5NigQ>? M4LWNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 Ml7ndWhVWyCjc4PhfS=> NHPhfGdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= M{jIZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 MVHxTHRUKGG|c3H5 NWrmT4o5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= M3fqdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 MkTMdWhVWyCjc4PhfS=> MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MlTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 MlLDdWhVWyCjc4PhfS=> Moq2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? NXPQcHJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Assay
Methods Test Index PMID
Western blot Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1 26655844
Immunofluorescence Cathepsin B 26655844
Growth inhibition assay Cell viability 25411356
体内研究 在DIO鼠中实施摄热量限制包括改善胰岛素敏感性,使葡萄糖和胰岛素水平维持正常,及提高线粒体能力后,可观察到SRT1720模拟一些功能。此外,在饮食导致的肥胖和遗传肥胖鼠中,SRT1720提高胰岛素敏感性,降低血浆葡萄糖,及提高线粒体能力。因此,SRT1720是有前途的新型治疗剂,可用于治疗像II型糖尿病之类的疾病。与提高的葡萄糖耐量相一致,在SRT1720处理的fa/fa鼠中,维持血糖正常所需的葡萄糖注入率(GIR)大约为35%, 全部的葡萄糖处理效率提高大约为20%。 [1] SRT1720作用于动物肿瘤模型研究时,抑制多发性骨髓瘤生长。SRT1720提高Bortezomib或Dexamethasone的毒性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
  • SIRT1荧光偏振实验:

    在SIRT1 FP试验中,使用从p53序列中得到的含20个氨基酸的肽段 (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly-Lys(MR121或 Tamra)-Glu-Glu-NH2)。肽段N端与生物素相连,C端用荧光标记修饰。监测酶活的反应是酶活偶联反应,第一步反应为SIRT1催化的脱乙酰反应,第二步反应为在新暴露的赖氨酸残基处进行胰蛋白酶催化的分裂。为了突出底物和产物的多种区别,加入链酶亲和素,反应终止。FP测试的敏感性可用来鉴定SRT1720。进行荧光偏振反应环境如下:0.5 μM 肽底物, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-醋酸盐(pH 为8), 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl2, 5 mM DTT, 0.025% BSA, 及0.15 mM烟碱。 反应在37oC温育,加入烟碱终止反应,加入胰蛋白酶分裂脱乙酰底物。加入链酶亲和素在37oC温育。在650 nm 和680nm 处测定荧光偏振。

细胞实验:[2]
  • Cell lines: 人类血管内皮细胞(HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2小时
  • Method: 使用Transwell迁移实验测定迁移率。通过基底膜的毛细血管样管结构形成试剂盒检测体外血管生成。用于内皮血管生成实验,从Clonetics获得的人类血管内皮细胞(HUVEC),保存在含5% FBS的内皮细胞生长培养基中。使用台盼蓝拒染法测定HUVEC细胞活力,观察到用SRT1720处理的细胞死亡率小于5%。
动物实验:[1]
  • Animal Models: 携带MM.1S细胞的Chase-SCID鼠
  • Dosages: 200 mg/kg
  • Administration: 口服处理

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 506.02
化学式

C25H23N7OS.HCl

CAS号 1001645-58-4
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
How can we prepare Srt1720 for in vivo mouse studies?

回答:
SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.